PointState Capital LP Acquires New Shares in Humana Inc (NYSE:HUM)

Share on StockTwits

PointState Capital LP acquired a new stake in shares of Humana Inc (NYSE:HUM) during the second quarter, according to its most recent filing with the SEC. The fund acquired 680,387 shares of the insurance provider’s stock, valued at approximately $180,507,000. Humana accounts for approximately 3.8% of PointState Capital LP’s investment portfolio, making the stock its 6th biggest holding. PointState Capital LP owned 0.50% of Humana as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Cornerstone Advisors Inc. increased its stake in Humana by 13.5% in the 2nd quarter. Cornerstone Advisors Inc. now owns 353 shares of the insurance provider’s stock worth $94,000 after acquiring an additional 42 shares during the last quarter. Regentatlantic Capital LLC increased its stake in Humana by 0.4% in the 2nd quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock worth $2,551,000 after acquiring an additional 42 shares during the last quarter. Cim Investment Mangement Inc. increased its stake in Humana by 4.3% in the 2nd quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock worth $298,000 after acquiring an additional 46 shares during the last quarter. Savant Capital LLC increased its stake in Humana by 2.5% in the 2nd quarter. Savant Capital LLC now owns 1,968 shares of the insurance provider’s stock worth $522,000 after acquiring an additional 48 shares during the last quarter. Finally, Greenleaf Trust increased its stake in Humana by 3.4% in the 2nd quarter. Greenleaf Trust now owns 1,652 shares of the insurance provider’s stock worth $438,000 after acquiring an additional 55 shares during the last quarter. Institutional investors own 92.77% of the company’s stock.

A number of brokerages have weighed in on HUM. Piper Jaffray Companies upped their target price on Humana from $315.00 to $341.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Morgan Stanley upped their price objective on Humana from $315.00 to $342.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Cantor Fitzgerald upgraded Humana from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $300.00 to $345.00 in a report on Monday, August 12th. UBS Group upped their price objective on Humana from $266.00 to $317.00 and gave the stock a “neutral” rating in a report on Thursday, August 1st. Finally, ValuEngine cut Humana from a “hold” rating to a “sell” rating in a report on Wednesday, September 11th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. Humana has an average rating of “Buy” and an average price target of $339.74.

In related news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the sale, the insider now directly owns 12,994 shares in the company, valued at approximately $3,764,361.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.54% of the company’s stock.

Shares of HUM traded up $5.32 during midday trading on Thursday, reaching $278.45. The stock had a trading volume of 65,962 shares, compared to its average volume of 855,916. The company’s 50-day moving average is $286.89 and its 200 day moving average is $268.64. Humana Inc has a 12-month low of $225.65 and a 12-month high of $355.88. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $37.04 billion, a price-to-earnings ratio of 19.13, a price-to-earnings-growth ratio of 1.20 and a beta of 0.84.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share for the quarter, beating the consensus estimate of $5.24 by $0.81. The company had revenue of $16.25 billion during the quarter, compared to analysts’ expectations of $15.88 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. Humana’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the prior year, the business posted $3.96 EPS. Research analysts forecast that Humana Inc will post 17.67 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend is Friday, September 27th. Humana’s dividend payout ratio is presently 15.12%.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: What does cost of debt say about a company’s financial health?

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.